---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-001074"
form_type: "8-K"
ticker: "XENE"
cik: "0001582313"
company_name: "Xenon Pharmaceuticals Inc."
filed_at: "2022-01-12T23:59:59+00:00"
generated_at: "2026-06-27T18:37:34.975035+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Xenon Pharma receives $15M milestone from Neurocrine after FDA accepts pediatric epilepsy study expansion

## Summary
- FDA accepted protocol amendment to expand Phase 2 study of NBI-921352 to children aged 2–11 with SCN8A-DEE.
- Xenon receives aggregate $15M: $6.75M cash plus $8.25M equity (258,986 shares at $31.855, a 15% premium to 30-day VWAP).
- Full IND acceptance triggered per amendment to 2019 Collaboration Agreement with Neurocrine Biosciences.
- Neurocrine's NBI-921352 is a selective Nav1.6 sodium channel inhibitor; two ongoing Phase 2 trials in epilepsy.
- Xenon potential for future clinical, regulatory, and commercial milestones plus royalties.

## SEC filing metadata
- accession: 0001564590-22-001074
- form_type: 8-K
- ticker: XENE
- cik: 0001582313
- company_name: Xenon Pharmaceuticals Inc.
- filed_at: 2022-01-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1582313/000156459022001074/0001564590-22-001074-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1582313/000156459022001074/xene-8k_20220111.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-001074
- JSON: https://secwatch.observer/filing/0001564590-22-001074.json
- Plain text: https://secwatch.observer/filing/0001564590-22-001074.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.